Skip to main content

Advertisement

SpringerLink
Log in

Future Directions in Research, Treatment and Prevention of HPV-Related Squamous Cell Carcinoma of the Head and Neck

  • Invited Review
  • Published:
Head and Neck Pathology Aims and scope Submit manuscript

Abstract

The causative relationship between high-risk HPV and OSCC is well-established. HPV-associated OSCC represents a distinct disease entity compared to tobacco-associated ones. These virus-associated cancers continuously express the HPV E6 and E7 viral oncogenes even in advanced stages, and repression of viral oncogene expression can prevent the growth or survival of cancer cells. This finding raises the possibility that even late-stage HPV-associated OSCC can be cured by HPV-targeted approaches, such as medicines that interfere with the expression or function of viral oncoproteins, and therapeutic vaccines that elicit a cytolytic immune response to cells expressing these oncoproteins. The demonstration that high-risk HPVs are causally associated with a subset of OSCC has allowed the development of preventive and therapeutic strategies aimed at reducing the incidence and mortality of this disease. The better outcome of HPV-associated OSCC raises the question as to whether similar results can be achieved with less treatment. An important aim of novel approaches for favorable-prognosis, HPV-associated cancers will be minimization of devastating side effects of intensified treatment developed for poor prognostic subsets. Clinical trials are studying the potential for de-escalation of radiation therapy in HPV + OSCC in the setting of different chemoradiotherapy regimens. The role of cetuximab in HPV-associated OSCC needs to be explored in prospective clinical trials. This review summarizes the main events of HPV-induced carcinogenesis with an emphasis on the implications of these carcinogenic mechanisms on research, treatment and prevention of HPV-associated OSCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Nat Cancer Inst. 2000;92(9):709–20.

    Article  PubMed  CAS  Google Scholar 

  2. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(5):736–47.

    Article  CAS  Google Scholar 

  3. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(32):4294–301.

    Article  Google Scholar 

  4. Goodwin EC, Yang E, Lee CJ, et al. Rapid induction of senescence in human cervical carcinoma cells. Proc Nat Acad Sci USA. 2000;97(20):10978–83.

    Article  PubMed  CAS  Google Scholar 

  5. Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78(21):11451–60.

    Article  PubMed  Google Scholar 

  6. Goodwin EC, DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Nat Acad Sci USA. 2000;97(23):12513–8.

    Article  PubMed  CAS  Google Scholar 

  7. Tan TM, Ting RC. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res. 1995;55(20):4599–605.

    PubMed  CAS  Google Scholar 

  8. Rampias T, Sasaki C, Weinberger P, et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Nat Cancer Inst. 2009;101(6):412–23.

    Article  PubMed  CAS  Google Scholar 

  9. Mellin H, Dahlgren L, Munck-Wikland E, et al. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer. 2002;102(2):152–8.

    Article  PubMed  CAS  Google Scholar 

  10. Van Tine BA, Dao LD, Wu SY, et al. Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning. Proc Nat Acad Sci USA. 2004;101(12):4030–5.

    Article  PubMed  Google Scholar 

  11. Strati K, Pitot HC, Lambert PF. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Nat Acad Sci USA. 2006;103(38):14152–7.

    Article  PubMed  CAS  Google Scholar 

  12. Rampias T, Boutati E, Pectasides E, et al. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res MCR. 2010;8(3):433–43.

    Article  CAS  Google Scholar 

  13. Hayward SD, Liu J, Fujimuro M. Notch and Wnt signaling: mimicry and manipulation by gamma herpesviruses. Sci STKE 2006;2006(335):re4.

    Google Scholar 

  14. Tumban E, Peabody J, Peabody DS, et al. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS ONE. 2011;6(8):e23310.

    Article  PubMed  CAS  Google Scholar 

  15. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–85.

    Article  PubMed  CAS  Google Scholar 

  16. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–8.

    Article  PubMed  Google Scholar 

  17. Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs. 2010;70(9):1079–98.

    Article  PubMed  Google Scholar 

  18. Lu B, Kumar A, Castellsague X, et al. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 2011;11:13.

    Article  PubMed  Google Scholar 

  19. D’Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Preventive Med. 2011;53(Suppl 1):S5–11.

    Article  Google Scholar 

  20. Maeda H, Kubo K, Sugita Y, et al. DNA vaccine against hamster oral papillomavirus-associated oral cancer. J Int Med Res. 2005;33(6):647–53.

    PubMed  CAS  Google Scholar 

  21. Romanowski B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccine. 2011;7(2):161–9.

    Article  Google Scholar 

  22. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25(26):4931–9.

    Article  PubMed  CAS  Google Scholar 

  23. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–47.

    Article  PubMed  CAS  Google Scholar 

  24. Vasan S, Hurley A, Schlesinger SJ, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS ONE. 2011;6(5):e19252.

    Article  PubMed  CAS  Google Scholar 

  25. Emens LA, Asquith JM, Leatherman JM, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(35):5911–8.

    Article  CAS  Google Scholar 

  26. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Nat Cancer Inst. 2008;100(4):261–9.

    Article  PubMed  CAS  Google Scholar 

  27. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(27):4142–8.

    Article  CAS  Google Scholar 

  28. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.

    Article  PubMed  CAS  Google Scholar 

  29. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol Off J Eur Soc Med Oncol (ESMO). 2011;22(5):1071–7.

    Article  CAS  Google Scholar 

  30. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.

    Article  PubMed  CAS  Google Scholar 

  31. Bonner JA, Ang K. More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med. 2007;357(18):1872–3.

    Article  PubMed  Google Scholar 

  32. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.

    Article  PubMed  CAS  Google Scholar 

  33. Koutcher L, Sherman E, Fury M, et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Rad Oncol Biol Phys. 2011;81(4):915–22.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2nd Department of Internal Medicine, Attikon Hospital, National Kapodistrian University of Athens, 12462, Athens, Greece

    Amanda Psyrri & George Dimitriadis

  2. Department of Surgery, Section of Otolaryngology, Yale University School of Medicine, New Haven, CT, 06511, USA

    Amanda Psyrri, Clarence Sasaki & Theodoros Rampias

  3. Department of Pathology, Yale University School of Medicine, New Haven, CT, 06511, USA

    Maria Vassilakopoulou

Authors
  1. Amanda Psyrri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Clarence Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Vassilakopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. George Dimitriadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Theodoros Rampias
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amanda Psyrri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Psyrri, A., Sasaki, C., Vassilakopoulou, M. et al. Future Directions in Research, Treatment and Prevention of HPV-Related Squamous Cell Carcinoma of the Head and Neck. Head and Neck Pathol 6 (Suppl 1), 121–128 (2012). https://doi.org/10.1007/s12105-012-0361-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12105-012-0361-8

Keywords

Search

Navigation